Karin Zibar Tomsic

Dr. Karin Zibar Tomsic

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 May 2017 in Endocrine Research
Verified
Journal Article
Closed access
KTKarin Zibar Tomsic
Karin Zibar Tomsic
TDTina Dušek
Tina Dušek
IKIvana Kraljević
Ivana Kraljević
ZHZdravko Heinrich
Zdravko Heinrich
MSMirsala Solak
Mirsala Solak
DKDarko Kaštelan
Darko Kaštelan
Purpose: The aim of the study was to investigate the incidence of and risk factors for hypopituitarism after gamma knife radiosurgery (GKRS) for pituitary adenoma. Materials and Methods: We conducted a retrospective analysis of the pituitary function of 90 patients who underwent GKRS for pituitary adenoma at the University Hospital Centre Zagreb between 2003 and 2014. Twenty seven of them met the inclusion criteria and the others were excluded from the study due to pituitary insufficiency which was present before GKRS. Eighteen patients had non-functioning and 9 patients had secretory adenomas. Median patients’ age was 56 years (24–82). GKRS was performed using the Leksell gamma knife Model C. The median prescription radiation dose was 20 Gy (15–25) and the median tumor volume size was 3.4 cm3 (0.06–16.81). New onset hypopituitarism was defined as a new deficit of one of the three hormonal axes (corticotroph, thyreotroph, or gonadotroph) ≥3 months following GKRS. SPSS was used for statistical analysis, with the significance level at P<0.05. Results: During the median follow-up period of 72 months (range 6–144), 30% of patients developed new hypopituitarism after GKRS. This corresponds to incidence of one new case of hypopituitarism per 15 patient-years. Age, gender, tumor function, tumor volume, suprasellar extension, prescription dose of radiation, as well as dose-volume to the pituitary gland, stalk and hypothalamus were not predictive factors for the development of hypopituitarism. Conclusions: In our cohort of patients with pituitary tumors who underwent GKRS, 30% developed new hypopituitarism during the follow-up period.

20 June 2022 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
ABAnnemarie Balasko
Annemarie Balasko
KTKarin Zibar Tomsic
Karin Zibar Tomsic
DKDarko Kastelan
Darko Kastelan
TDTina Dusek
Tina Dusek

14 July 2022 in Clinical Endocrinology
Verified
Journal Article
Closed access
KTKarin Zibar Tomsic
Karin Zibar Tomsic
TDTina Dusek
Tina Dusek
AAAnamarija Alduk
Anamarija Alduk
NKNikola Knezevic
Nikola Knezevic
VMVilim Molnar
Vilim Molnar
DKDarko Kastelan
Darko Kastelan

8 July 2014 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
KTKarin Zibar Tomsic
Karin Zibar Tomsic
JĆJadranka Knežević Ćuća
Jadranka Knežević Ćuća
KBKristina Blaslov
Kristina Blaslov
TBTomislav Bulum
Tomislav Bulum
LSLea Smirčić-Duvnjak
Lea Smirčić-Duvnjak
Background: The role of glucagon-like peptide-1 (GLP-1) has become a new scientific interest in the field of pathophysiology of type 1 diabetes mellitus (T1DM), but the results of the published studies were contradictory. The aim of our study was therefore to measure fasting and postprandial GLP-1 concentrations in T1DM patients and in healthy controls and to examine the difference in those concentrations between the two groups of subjects. Methods: The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20–59), with disease duration 22 years (3–45), and 10 healthy controls, median age 30 years (27–47). Fasting and postprandial total and active GLP-1 concentrations were measured by ELISA (ALPCO, USA). The data were statistically analysed by SPSS, and significance level was accepted at P < 0.05. Results: Both fasting total and active GLP-1 concentrations were significantly lower in T1DM patients (total 0.4 pmol/L, 0–6.4 and active 0.2 pmol/L, 0–1.9) compared with healthy controls (total 3.23 pmol/L, 0.2–5.5 and active 0.8 pmol/L, 0.2–3.6), P = 0.008 for total GLP-1 and P = 0.001 for active GLP-1. After adjustment for age, sex and body mass index, binary logistic regression showed that both fasting total and active GLP-1 remained significantly independently lower in T1DM patients (total GLP-1: OR 2.43, 95% CI 1.203–4.909 and active GLP-1: OR 8.73, 95% CI 1.472–51.787). Conclusions: T1DM patients had independently lower total and active GLP-1 fasting concentrations in comparison with healthy people, which supports the potential therapeutic role of incretin therapy, along with insulin therapy, in T1DM patients.

1 April 2017 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
LZLada Zibar
Lada Zibar
KTKarin Zibar Tomsic
Karin Zibar Tomsic
Metformin is a first-line oral antidiabetic therapy for patients with type 2 diabetes mellitus. Metformin-associated lactate acidosis (MALA) is a well-known, life-threatening, but rare side effect of metformin therapy. Chronic kidney disease (CKD) patients have a much greater risk of MALA. We report the case of a severe refractory MALA despite hemodialysis (HD) treatment, associated with hypoglycemia, hypothermia, and bradycardia in a neglected and thus untimely-recognized CKD patient with type 2 diabetes mellitus. Despite the recent rehabilitation of metformin as a treatment of choice for type 2 diabetes mellitus, the drug should be prescribed with caution as it can be associated with life-threatening refractory acidosis, particularly in CKD patients. Moreover, HD treatment could occasionally be ineffective, resulting in a fatal outcome. .